Ebola Vaccine Tested in DR Congo Outbreak Zone

Health workers in the Democratic Republic of Congo launched a test vaccination program on September 20, 2026, targeting 20,000 frontline personnel in Ituri and North-Kivu provinces with the Ervebo vaccine to combat a deadly outbreak of the Bundibugyo strain. According to country authorities, the ongoing epidemic has caused 3,639 deaths out of 7,541 confirmed cases, marking a 48.3% fatality rate.

Vaccinating Frontline Workers Against the Bundibugyo Strain

The immunization study runs for up to a year with backing from the World Health Organization and Doctors Without Borders. According to official figures, the outbreak stems from the Bundibugyo variant, which currently lacks any approved treatment or vaccine. Officials designed the rollout to see if the Ervebo jab—originally developed for the Zaire strain—offers cross-protection against this distinct variant.

We don’t know to what degree it might be effective against the Bundibugyo strain, said Steve Ahuka, a Congolese official on the Ebola health task force. Nana Mimbu, a research coordinator for Doctors Without Borders, noted that the vaccine might offer a certain level of cross-protection.

Did you know? The Democratic Republic of Congo’s current epidemic carries a 48.3% fatality rate, with 3,639 deaths recorded out of 7,541 confirmed cases.

Assessing Transmission Rates and Vaccine Supplies

World Health Organization experts cited encouraging signs that transmission may be slowing down in affected regions. However, Doctors Without Borders warned on September 18, 2026, that clear evidence proving the epidemic is coming under control remains absent.

Early data from animal trials suggest the Ervebo vaccine could provide some defense during the outbreak, according to United Nations health agency experts. Last month, the UN health agency announced that pharmaceutical company Merck manufactured 70,000 doses in Germany for shipment to the Democratic Republic of Congo.

Pro Tip: Monitor updates from the World Health Organization and local health ministries for verified epidemiological data and vaccination rollout milestones.

Frequently Asked Questions

What causes the current Ebola outbreak in the Democratic Republic of Congo?

The current epidemic is caused by the Bundibugyo strain of the virus, which currently lacks any approved treatment or vaccine.

Which vaccine is being tested in the new program?

Health workers are testing the Ervebo vaccine, which was originally developed by Merck for the Zaire strain, to evaluate potential cross-protection against the Bundibugyo variant.

From Instagram — related to ebola vaccine tested congo, vaccin Ervebo RD Congo

How many people are receiving the vaccine in this study?

The study targets 20,000 frontline health personnel across the Ituri and North-Kivu provinces over a period lasting up to a year.

Who is supporting the vaccination study?

The operation is backed by the World Health Organization and the Doctors Without Borders charity.


Join the Conversation: Share your thoughts on this vaccination study in the comments below, or subscribe to our newsletter for ongoing updates on global health developments.

Ebola : un premier vaccin expérimental contre Bundibugyo testé en RDC

Leave a Comment